Life science organizations play a vital role in fighting the coronavirus pandemic. We know that conquering a disease that is putting considerable strain on current healthcare services and sending economic shockwaves around the globe is of paramount importance. Atos is uniquely positioned to enable life sciences and other research organizations to:
- Reduce R&D costs through digital applications in the clinical trial phase, ensuring full regulatory compliance through the TMF process
- Reduce costs through digitally enabled operational efficiencies in the drug manufacturing phase
- Accelerate speed to market for drugs and vaccines, reducing costs to market and maintaining competitive advantage
- Innovate your digital workplace with a secure and cost-effective methodology, delivering flexibility and greater productivity.
Business Continuity
Increased demand
Expert resource & staff with critical skills to support rapid digital change and service delivery.
Support centers
Maintaining patient trial, contact and support services via remote, geo-redundant contact centers.
Employee Continuity
Physical Enablement
Ensuring your staff have the equipment they need to work effectively from any location.
Virtual Enablement
Selection, deployment and optimization of remote working software and virtual desktop infrastructure to support home and anywhere working.
Data & Security Continuity
Data & security regulatory compliance
Providing advisory services around data practices to ensure certainty of compliance during homeworking.
Increase in cyber security threats and attacks
Protecting vital services and confidential information from unwarranted attacks.
Meet our customers:
Atos’ Canopy Open Hybrid Cloud platform, launched in 1H19, will support Philips on its journey toward cloud-native application delivery services over the next few years.
Johnson & Johnson has renewed its contract with Atos to deploy Digital Workplace technologies across its organization to improve productivity while also controlling costs.
Further Reading
